EXAS实时信号 | 通过Getagraph.com最大化利润

出售 12 min ago

@ $59.37

发出时间: 29 Apr 2024 @ 21:32

回报率: 0.51%

上一信号: Apr 27 - 00:30

上一信号: 购买

回报率: 0.53 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 21:45):

Stats
今日成交量	118 410
平均成交量	2.50M
市值	10.83B
EPS	$0 ( 2024-02-21 )
下一个收益日期	( $-0.500 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-52.80
ATR14	$1.801 (3.03%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Condella Sarah	Sell	2 000	Common Stock
2024-04-02	Baranick Brian	Sell	924	Common Stock
2024-03-28	Condella Sarah	Sell	2 000	Common Stock
2024-02-29	Orville Jacob A	Buy	4 724	Common Stock
2024-03-01	Orville Jacob A	Sell	2 154	Common Stock

INSIDER POWER
36.33
Last 100 transactions
Buy: 542 709 \| Sell: 252 987

音量相关性

長: -0.75 (moderate negative)

短: 0.57 (weak)

Signal:(61) Neutral

Exact Sciences Corp 相关性

10 最正相关
AVEO	0.942
ITMR	0.941
HZNP	0.928
LUNA	0.926
WLFC	0.925
MLCO	0.923
FCBP	0.922
NWLI	0.92
OBAS	0.916
NWFL	0.914

10 最负相关
GOSS	-0.97
VS	-0.951
XFOR	-0.95
GROM	-0.938
TOPS	-0.933
USEG	-0.932
QTEK	-0.931
TRVN	-0.931
SG	-0.93
THTX	-0.929

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Exact Sciences Corp 相关性 - 货币/商品

0.59
( weak )

0.58
( weak )

0.00
( neutral )

0.68
( moderate )

0.60
( weak )

-0.47
( neutral )

Exact Sciences Corp 财务报表

Annual	2023
营收:	$2.50B
毛利润:	$1.85B (73.83 %)
EPS:	$-1.130

FY	2023
营收:	$2.50B
毛利润:	$1.85B (73.83 %)
EPS:	$-1.130

FY	2022
营收:	$2.08B
毛利润:	$1.51B (72.44 %)
EPS:	$-3.54

FY	2021
营收:	$1.77B
毛利润:	$1.31B (74.04 %)
EPS:	$-3.48

Financial Reports:

No articles found.

Exact Sciences Corp

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.